- 商品介绍
- 规格参数
- 包装参数
General description
Effective therapy for partial seizures in adults and childhood seizures in Lennox-Gastaut syndrome.
Application
Rufinamide has been used to test its analgesic effect on neuropathic pain in spared nerve injury (SNI) model.
Biochem/physiol Actions
Rufinamide may elicit inhibition of the sodium channels and block action potential generation. This property makes it an antiepileptic drug for treating epilepsy disorders like Lennox-Gastaut syndrome.
Broad-spectrum anticonvulsant.
Features and Benefits
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white |
| solubility | DMSO: 9 mg/mL |
| originator | Novartis |
| storage temp. | −20°C |
| SMILES string | NC(=O)c1cn(Cc2c(F)cccc2F)nn1 |
| InChI | 1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17) |
| InChI key | POGQSBRIGCQNEG-UHFFFAOYSA-N |
| Gene Information | human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335) |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
-
询价
-
¥ 2707.32
-
询价
-
¥ 2290.21
-
¥ 1259.40
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
询价
-
¥ 4390.38
-
询价
-
¥ 1568.60
-
询价
-
¥ 5014.59
-
¥ 2869.87
微信小程序
7X24小时在线咨询